Elutia closes $88 million sale of BioEnvelope business to Boston Scientific

The sale and what it leaves

Elutia Inc. (Nasdaq: ELUT) said on October 1, 2025 that it has closed the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX) for $88 million in cash. The business comprises the EluPro and CanGaroo bioenvelopes. EluPro carries antibiotics, and according to the 2024 annual report it is the only drug-eluting biomatrix offering in the U.S. implantable electronic device protection market. CanGaroo uses the same biomatrix without antibiotics. With the sale closed, Elutia says it will focus on NXT-41x, a biomatrix for reconstruction infections after mastectomy. The release says NXT-41x combines biologics with extended antibiotic release. CEO Randy Mills said the company has a "significantly strengthened" financial position and plans to bring NXT-41x to market in the first half of 2027. He also spoke of accelerating the company's path to positive cash flow. The release does not say whether NXT-41x has regulatory clearance or approval, and it gives no clinical data for it. The first half of 2027 is the company's own target.

The balance sheet claim

The release's headline says the sale gives a strengthened balance sheet to fully fund development and launch of the NXT-41 platform. The body makes the same claim. It gives no cash balance after closing, no figure for how much of the $88 million goes to debt, and no budget for the launch. The release's own list of risks sits against the headline. It names the company's ability to continue as a going concern, its ability to manage significant indebtedness including a Revenue Interest Obligation to Ligand Pharmaceuticals Incorporated, and lawsuits related to its former FiberCel and VBM products. Its forward-looking statements also cover whether the sale proceeds will be sufficient to develop and commercialize the pipeline. The release does not describe the FiberCel and VBM lawsuits or the amount at stake.

The market and the company's record

The release says more than 150,000 breast reconstruction procedures are performed in the U.S. each year, that about one in three patients suffers serious complications, and that biologics account for 65% of implant-based costs. It puts the U.S. market opportunity at $1.5 billion. These are the company's estimates. The release gives no source for them. The company has sold businesses before. Its 2024 annual report describes the sale of its Orthobiologics business to Berkeley in November 2023, for approximately $14.6 million plus up to an additional $20 million in earn-out payments. Under that deal, earn-outs equal 10% of Berkeley's revenue in each of five years after closing. The company still receives SimpliDerm under a contract manufacturing relationship with Berkeley, the report says. The report also lists Roswell, Georgia as the processing and production site for its implantable device and cardiovascular products, with headquarters in Silver Spring, Maryland. The release is datelined Gaithersburg, Maryland. The report estimates more than 700,000 surgical procedures a year in the U.S. involve implanted devices such as pacemakers, defibrillators, neurostimulators and breast tissue expanders.

Who is named

The release names Boston Scientific as the buyer and names no financial adviser, placement agent or counsel for the sale. Its investor contact is Matt Steinberg of FINN Partners, and the release does not say whether any adviser was paid for the sale.

Report an error

Companies in this story

ELUTElutia, Inc.NASDAQ · United StatesOpen the starter deskBSXBOSTON SCIENTIFIC CORPNYSE · United StatesOpen the starter desk